A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: An Eastern Cooperative Oncology Group Study (E8188)

Cancer

Volumn 92, Issue 10, 2001, Pages 2517-2522

  Gradishar, William J ^a,b,c   Stephenson, Patricia ^a,b,g,h   Glover, Donna J ^a   Neuberg, Donna S ^b   Moore, Melvin R ^c   Windschitl, Harold E ^d   Piel, Ira ^e   Abeloff, Martin D ^f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^d GRADY MEMORIAL HOSPITAL   (United States)

^e St Cloud State University   (United States)

^f ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Amifostine; Breast neoplasm; Chemoprotection; Cisplatin; Nephrotoxicity; Neurotoxicity; Ototoxicity

Indexed keywords

ALKYLATING AGENT; AMIFOSTINE; CISPLATIN; MANNITOL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; METASTASIS; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CISPLATIN; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; NERVOUS SYSTEM DISEASES; RADIATION-PROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 0035889876     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20011115)92:10<2517::AID-CNCR1602>3.0.CO;2-Z     Document Type: Article

References (34)

1. Cisplatin in the management of breast cancer
2. Cisplatin as first-line therapy for metastatic breast cancer
3. Cisplatin in the treatment of metastatic breast cancer
4. Amifostine: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies
5. Technical papers. Cysteine protection against x irradiation
6. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector
7. Biological characteristics of some improved radioprotectors
8. Selective inhibition of the nephrotoxicity of cis-dichlorodiammine platinum (II) by WR-2721 without altering its antitumor properties
9. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine
10. The role of WR-2721 in radiotherapy and/or chemotherapy
11. A more general role for WR-2721 in cancer therapy
12. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide
13. The role of WR-2721 in radiotherapy and/or chemotherapy
14. PhaseI trials of WR-2721 and cis-platinum
15. Clinical trials of WR-2721 and cis-platinum
16. Phase I/II trials of WR-2721 and cis-platinum
17. Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721
18. Toxicity and response criteria of the Eastern Cooperative Oncology Group
19. Nonparametric estimation from incomplete observations
20. Time dependence of the selective modulation of cisplatininduced nephrotoxicity by WR2721 in the mouse
21. WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells
22. Ototoxicity of low and moderate dose cisplatin
23. Peripheral sensory neuropathy and cisplatin chemotherapy
24. High dose cisplatin (C) and WR2721 in metastatic melanoma
25. Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer
26. Amifostine and chemotherapy-related thromboytopenia
27. Randomized phase II study of weekly cisplatin with or without amifostine in patient with advanced head and neck cancer
28. Randomized trial of carboplatin (CBDCA) v CBDCA + amifostine (AMI) in advanced malignancy
29. Mature results of a randomized trial of carboplatin (C) and amifostine (A) vs. C alone in patients (pts) with advanced malignancies
30. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small cell lung cancer: A randomized phase II study
31. Amifostine, cisplatin and vinblastine in metastatic nonsmall cell lung cancer: A report of high response rates and prolonged survival
32. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer
33. Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer